PC
RPRX

Paulson & Co’s Repros Therapeutics Inc. RPRX Stock Holding History

Paulson & Co’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,000,000
Closed -$9.9M – 78
2014
Q3 		$9.9M Buy
+1,000,000
New +$14.8M 0.04% 68

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paulson & Co's RPRX Position: Q4 2014 in Review

Paulson & Co sold out of Repros Therapeutics Inc. (RPRX) in Q4 2014, closing a stake of 1,000,000 shares — an estimated $9.9M sold.

Paulson & Co first reported a position in RPRX in Q3 2014 and held it in 1 quarter. The position peaked at $9.9M in Q3 2014. 80 funds tracked by Wall St. Rank hold RPRX as of Q4 2014.

  • Paulson & Co reported no remaining Repros Therapeutics Inc. position as of Q4 2014 after selling out during the quarter.
  • Paulson & Co sold 1,000,000 Repros Therapeutics Inc. shares in Q4 2014, an estimated $9.9M.
  • Paulson & Co first reported a position in Repros Therapeutics Inc. in Q3 2014 and held it in 1 quarter.
  • Paulson & Co's Repros Therapeutics Inc. position peaked at $9.9M in Q3 2014.
  • 80 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2014.

Based on Paulson & Co's 13F filing for Q4 2014, filed 17 Feb 2015.